Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibiotic OMN6 tested against tough lung infection

NCT ID NCT06087536

Disease control Sponsor: Omnix Medical Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This phase 2a trial tests an experimental antibiotic called OMN6 in 54 adults with hospital-acquired or ventilator-associated pneumonia caused by Acinetobacter baumannii. Participants receive either OMN6 or a placebo, plus standard antibiotics, for one day. The main goal is to check safety and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
OMN6 (an experimental antibiotic given intravenously)
What this could lead to
If successful, this could point toward a new treatment option for a hard-to-treat lung infection in hospitalized patients.
What could go wrong
This is an early phase 2a trial with only 54 participants, focused on safety and dosing—not yet on effectiveness. The drug is given for just one day alongside standard antibiotics, so its added benefit is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 54 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. A signed informed consent form. 2. Male or female patients 18 years or older 3. A diagnosis of either a HABP or a VABP 4. ABC infection of the lower respiratory tract suspected based on a positive rapid testing of respiratory specimens 5. Women of childbearing potential (WOCBP) (i.e., not post-menopausal or surgically sterilized) must have a negative highly sensitive urine or serum pregnancy test before randomization. 6. Acute Physiology and Chronic Health Evaluation II (APACHE II) score between 10 and 24 Exclusion Criteria: 1. Moderate to severe reduction of renal function 2. Liver dysfunction 3. Evidence of septic shock 4. Acute respiratory distress syndrome. 5. Immunosuppressed patients (due to either immunosuppressant drugs or to any medical condition). 6. History of any known hypersensitivity to colistin or to carbapenems 7. Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the study data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hospital-acquired bacterial pneumonia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nosocomial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hospital-acquired bacterial pneumonia Ventilator associated bacterial pneumonia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Omnix Medical Research Site

    RECRUITING

    Ashdod, Israel

  • Omnix Medical Research Site

    RECRUITING

    Be’er Ya‘aqov, Israel

  • Omnix Medical Research Site

    RECRUITING

    Holon, Israel

  • Omnix Medical Research Site

    RECRUITING

    Petah Tikva, Israel

  • Omnix Medical Research Site

    RECRUITING

    Ramat Gan, Israel

  • Omnix Medical Research Site

    RECRUITING

    Rishon LeZiyyon, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.